Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum.
Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate cancer. To date, no effective therapy is available for clinically hormone-insensitive or hormone-refractory stages of prostate cancer.
Mahajna
Jamal
J
Cancer Drug Discovery Program, Migal-Galilee Technology Center, Kiryat Shmona, Israel. jamalm@migal.org.il
Dotan
Nesly
N
Zaidman
Ben-Zion
BZ
Petrova
Roumyana D
RD
Wasser
Solomon P
SP
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism; D020940:Reishi / Q000737:chemistry*; D015398:Signal Transduction
D000970:Antineoplastic Agents; D011944:Receptors, Androgen